Close this search box.


CanSino Biologics signs collaborative agreement with SPIMACO to develop innovative new vaccines

CanSino Biologics, a Chinese biotech company and vaccine developer, has signed an agreement with SPIMACO, a publicly listed Saudi Pharmaceutical company, to deepen their strategic partnership. Both companies will cooperate in commercializing new vaccines, collaborate on vaccine and clinical research and localize manufacturing. In particular, the collaboration will focus on promoting the Manhexin® vaccine for meningitis in Saudi Arabia and the MENA region.